Manuela Gambella

899 total citations
13 papers, 283 citations indexed

About

Manuela Gambella is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Manuela Gambella has authored 13 papers receiving a total of 283 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Hematology, 5 papers in Molecular Biology and 4 papers in Oncology. Recurrent topics in Manuela Gambella's work include Multiple Myeloma Research and Treatments (10 papers), Protein Degradation and Inhibitors (4 papers) and Peptidase Inhibition and Analysis (2 papers). Manuela Gambella is often cited by papers focused on Multiple Myeloma Research and Treatments (10 papers), Protein Degradation and Inhibitors (4 papers) and Peptidase Inhibition and Analysis (2 papers). Manuela Gambella collaborates with scholars based in Italy, United Kingdom and United States. Manuela Gambella's co-authors include Antonio Palumbo, Alberto Rocci, Mario Boccadoro, Paola Omedè, Stefania Oliva, Francesca Gay, Sara Bringhen, Daniela Natale, Richard O. Hynes and Ignazio Majolino and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Manuela Gambella

12 papers receiving 281 citations

Peers

Manuela Gambella
Esther Tijchon Netherlands
Y-T Tai United States
Caroline Alvares United Kingdom
Annegret Rosemann Germany
Marco De Dominici United States
Nirmalee Abayasekara United States
Susan A. Heilman United States
Silvia Ling Australia
Colin A. Martz United States
Esther Tijchon Netherlands
Manuela Gambella
Citations per year, relative to Manuela Gambella Manuela Gambella (= 1×) peers Esther Tijchon

Countries citing papers authored by Manuela Gambella

Since Specialization
Citations

This map shows the geographic impact of Manuela Gambella's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manuela Gambella with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manuela Gambella more than expected).

Fields of papers citing papers by Manuela Gambella

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Manuela Gambella. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manuela Gambella. The network helps show where Manuela Gambella may publish in the future.

Co-authorship network of co-authors of Manuela Gambella

This figure shows the co-authorship network connecting the top 25 collaborators of Manuela Gambella. A scholar is included among the top collaborators of Manuela Gambella based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Manuela Gambella. Manuela Gambella is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Martinuzzi, Emanuela, Angela Puma, Luisa L. Villa, et al.. (2025). Interleukin‐6 as a Key Biomarker in Facioscapulohumeral Dystrophy: Evidence From Longitudinal Analyses. Annals of Clinical and Translational Neurology. 13(2). 310–323.
2.
D’Agostino, Mattia, Gian Maria Zaccaria, Bachisio Ziccheddu, et al.. (2020). Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing. Clinical Cancer Research. 26(18). 4832–4841. 38 indexed citations
3.
D’Agostino, Mattia, Gian Maria Zaccaria, Bachisio Ziccheddu, et al.. (2019). Clinical and Biological Early Relapse Predictors in Multiple Myeloma: An Analysis from the MMRF CoMMpass Study. Clinical Lymphoma Myeloma & Leukemia. 19(10). e13–e14. 1 indexed citations
4.
5.
Glavey, Siobhan, Alexandra Naba, Salomon Manier, et al.. (2017). Proteomic characterization of human multiple myeloma bone marrow extracellular matrix. Leukemia. 31(11). 2426–2434. 65 indexed citations
6.
Oliva, Stefania, Manuela Gambella, Mario Boccadoro, & Sara Bringhen. (2017). Systemic virotherapy for multiple myeloma. Expert Opinion on Biological Therapy. 17(11). 1–13. 12 indexed citations
7.
Oliva, Stefania, Davine Hofste op Bruinink, Lucie Říhová, et al.. (2017). Minimal residual disease (MRD) monitoring by multiparameter flow cytometry (MFC) in newly diagnosed transplant eligible multiple myeloma (MM) patients: Results from the EMN02/HO95 phase 3 trial.. Journal of Clinical Oncology. 35(15_suppl). 8011–8011. 13 indexed citations
8.
9.
Gambella, Manuela, Antonio Palumbo, & Alberto Rocci. (2015). MET/HGF pathway in multiple myeloma: from diagnosis to targeted therapy?. Expert Review of Molecular Diagnostics. 15(7). 881–893. 12 indexed citations
10.
Gambella, Manuela, Alberto Rocci, Roberto Passera, et al.. (2014). High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib. Haematologica. 99(2). e14–e16. 47 indexed citations
11.
Gambella, Manuela, Paola Omedè, Stefania Oliva, et al.. (2014). In Multiple Myeloma, Minimal Residual Disease (MRD) Is an Early Predictor of Progression and Is Modulated By Maintenance Therapy with Lenalidomide. Blood. 124(21). 3394–3394. 2 indexed citations
12.
Drandi, Daniela, Lenka Sedlaříková, Stefania Oliva, et al.. (2014). Cell-Free DNA for Minimal Residual Disease Monitoring in Multiple Myeloma Patients. Blood. 124(21). 3423–3423. 4 indexed citations
13.
Bonanno, Giuseppina, Andrea Mariotti, Annabella Procoli, et al.. (2012). Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma. Journal of Translational Medicine. 10(1). 247–247. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Esther Tijchon Breakdown of academic impact, for papers by Y-T Tai Breakdown of academic impact, for papers by Caroline Alvares Breakdown of academic impact, for papers by Annegret Rosemann Breakdown of academic impact, for papers by Marco De Dominici Breakdown of academic impact, for papers by Nirmalee Abayasekara Breakdown of academic impact, for papers by Susan A. Heilman Breakdown of academic impact, for papers by Silvia Ling Breakdown of academic impact, for papers by Colin A. Martz
Rankless by CCL
2026